Stifel Remains a Buy on Artivion (AROT)

Artivion, Inc. (NYSE:AORT) is one of the Best Small-Cap Growth Stocks to Buy According to Hedge Funds. On March 5, Artivion, Inc. (NYSE:AORT) was reiterated with a Buy rating by analyst John McAulay of Stifel with a price target of $55.

​The analyst said in a research note that the Buy rating is based on the company’s promising aortic disease pipeline. He highlighted Artivion’s NEXUS stent graft system as the next key launch for treating chronic aortic arch dissections and aneurysms, estimating a $150 million US total addressable market. The analyst noted that the one-year results from the NEXUS TRIOMPHE pivotal trial were shared at the Society of Thoracic Surgeons meeting in late January 2026. The data showed strong sealing performance and low endoleak rates.

​The analyst interviewed three physicians experienced with NEXUS implants who intend to adopt it post-FDA approval. These discussions evaluated trial data strength, approval odds, and market uptake potential, informing the note’s optimistic outlook.

​Artivion, Inc. (NYSE:AORT) manufactures and distributes medical devices and implantable human tissues for cardiac and vascular surgeries, primarily targeting aortic diseases.

While we acknowledge the potential of AORT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. Follow Insider Monkey on Google News.